en · de · es · fr · pt
glossary-desk.peptides6155.com › Info › Tb-500 Identity And Molecular Background — Hands-On Walkthrough

Tb-500 Identity And Molecular Background — Hands-On Walkthrough

By Editorial Desk · published 2026-04-07 · last reviewed 2026-05-17 · Info

The short version of LKKTETQ fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-05-17 and is reviewed periodically as new material appears.

TB-500 Identity and Molecular Background

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Handling, Storage and Analytical Checks

Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.

Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.

Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Calculated for the acetylated heptapeptide
Molecular weight~889 DaMonoisotopic mass approximately 889.0 Da
Amino acid sequenceAc-LKKTETQN-terminal acetylated seven-residue peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilized solid
Solubility classWater-solublePeptides of this size generally dissolve in aqueous media

Handling, Stability and Analytical Detection

Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.

Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.

Related pages on this site

TB-500 Identity and Chemical Background

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

TB-500 Identity and Naming Background

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Background from the literature

The role of FICD in BiP AMPylation (and de-AMPylation) on Thr518 is well supported by biochemical and structural studies. Evidence has also been presented that in some circumstances FICD may AMPylate a different residue, Thr366 in BiP's nucleotide binding domain.

From a clinical perspective, two significant school of thought exists for psychiatric conditions associated with cannabis (or cannabinoids) use: transient, non-persistent psychotic reactions, and longer-lasting, persistent disorders that resemble schizophrenia. The former is formally known as acute cannabis-associated psychotic symptoms (CAPS) or cannabis-induced psychotic disorder (CIPD). At an epidemiological level, a dose–response relationship exists between cannabis use and increased risk of psychosis and earlier onset of psychosis. Although the epidemiological association is robust, evidence to prove a causal relationship is lacking. Cannabis may also increase the risk of depression, but insufficient research has been performed to draw a conclusion. A 2014 meta-analysis of longitudinal studies found that cannabis use was associated with a modestly increased risk of developing depressive disorders, particularly among heavy users, although the causal relationship remains uncertain and further research is needed. Cannabis use is associated with increased risk of anxiety disorders, although causality has not been established. A 2025 systematic review and meta-analysis involving more than half a million participants aged 15–30 reported that cannabis use was associated with higher odds of depression (51% higher), anxiety (58%), suicidal ideation (65%), and suicide attempt (87%). A review in 2019 found that research was insufficient to determine the safety and efficacy of using cannabis to treat schizophrenia, psychosis, or other mental disorders.

=== Clinical trials === Bhatt has served as principal investigator, co-principal investigator, or steering-committee chair for multiple large, multicenter randomized controlled trials examining strategies to reduce cardiovascular events in high-risk patients. His work has included studies of sodium–glucose cotransporter2 (SGLT2) based therapies in patients with diabetes and either heart failure or chronic kidney disease, high-dose eicosapentaenoic acid (icosapent ethyl) in statin-treated patients with elevated triglycerides, intravenous antiplatelet therapy during percutaneous coronary intervention, and intensified oral antiplatelet regimens in patients with stable coronary artery disease and diabetes. His publication record includes work on standardized bleeding definitions for cardiovascular trials, stroke and acute coronary syndrome guidelines, and large outcome studies in diabetes and chronic kidney disease, many of which are highly cited and have been referenced in clinical practice discussions and educational materials in cardiology and stroke medicine.

1905: American geneticist Nettie Stevens discovered sex chromosomes. 1906: Following the San Francisco earthquake, American botanist and curator Alice Eastwood rescued almost 1500 rare plant specimens from the burning California Academy of Sciences building. Her curation system of keeping type specimens separate from other collections – unconventional at the time – allowed her to quickly find and retrieve the specimens. 1906: Russian chemist Irma Goldberg published a paper on two newly discovered chemical reactions involving the presence of copper and the creation of a nitrogen-carbon bond to an aromatic halide. These reactions were subsequently named the Goldberg reaction and the Jourdan-Ullman-Goldberg reaction. 1906: English physicist, mathematician and engineer Hertha Ayrton became the first female recipient of the Hughes Medal from the Royal Society of London. She received the award for her experimental research on electric arcs and sand ripples. 1906: After her death, English lepidopterist Emma Hutchinson's collection of 20,000 butterflies and moths was donated to the London Natural History Museum. She had published little during her lifetime, and was barred from joining local scientific societies due to her gender, but was honoured for her work when a variant form of the comma butterfly was named hutchinsoni. 1907: Swedish-Norwegian physicist and nutritionist Signe Schmidt-Nielsen became one of the first women in Sweden to receive a doctoral degree. She was also the first woman to become a member of the Royal Norwegian Society of Sciences and Letters.

Sources: en.wikipedia.org

Further detail

Inhalation of environmental and occupational pollutants, such as metals in asbestosis, silicosis, and exposure to certain gases. Coal miners, ship workers and sand blasters, among others, are at higher risk. Hypersensitivity pneumonitis, most often resulting from inhaling dust contaminated with bacterial, fungal, or animal products Cigarette smoking can increase the risk or make the illness worse. Smoking is a known cause of some types of lung fibrosis, such as smoking-related interstitial fibrosis (SRIF). Some typical connective tissue diseases such as rheumatoid arthritis, ankylosing spondylitis, SLE and scleroderma Other diseases that involve connective tissue, such as sarcoidosis and granulomatosis with polyangiitis Infections, including COVID-19 Certain medications, e.g. amiodarone, bleomycin (pingyangmycin), busulfan, apomorphine, and nitrofurantoin Radiation therapy to the chest

Adaptogens are plants that support health through nonspecific effects, neutralize various environmental and physical stressors while being relatively safe and free of side effects. As of 2008, the position of the European Medicines Agency was that "The principle of an adaptogenic action needs further clarification and studies in the pre-clinical and clinical area." As such, the term is not accepted in pharmacological and clinical terminology that is commonly used in the EU."

20,000, 11 December 2007- On 29 October 2007, the SENSEX crossed the 20,000 mark for the first time with a massive 734.5-point gain, but closed below the 20,000 mark. The SENSEX would close above the 20,000 mark for the first time on 11 December 2007. It took 42 days after reaching the 19,000 milestone to close above 20,000 points for the first time. The journey of the last 10,000 points was covered in just 483 sessions, compared to 7,297 sessions taken to touch the 10,000 mark from its base value of 100 points. In the second half of 2007 alone, the SENSEX reached six 1,000-point milestones.

Hydroponics is a type of horticulture and a subset of hydroculture which involves growing plants, usually crops or medicinal plants, without soil, by using water-based mineral nutrient solutions in an artificial environment. Terrestrial or aquatic plants may grow freely with their roots exposed to the nutritious liquid or the roots may be mechanically supported by an inert medium such as perlite, gravel, or other substrates. Despite inert media, roots can cause changes of the rhizosphere pH and root exudates can affect rhizosphere biology and physiological balance of the nutrient solution when secondary metabolites are produced in plants. Transgenic plants grown hydroponically allow the release of pharmaceutical proteins as part of the root exudate into the hydroponic medium. The nutrients used in hydroponic systems can come from many different organic or inorganic sources, including fish excrement, duck manure, purchased chemical fertilizers, or artificial standard or hybrid nutrient solutions. In contrast to field cultivation, plants are commonly grown hydroponically in a greenhouse or contained environment on inert media, adapted to the controlled environment agriculture (CEA) process. Plants commonly grown hydroponically include tomatoes, peppers, cucumbers, strawberries, lettuces, and cannabis, usually for commercial use, as well as Arabidopsis thaliana, which serves as a model organism in plant science and genetics. Hydroponics offers many advantages, notably a decrease in water usage in agriculture. To grow 1 kilogram (2.2 lb) of tomatoes using

Galanin-like peptide (GALP) is a neuropeptide present in humans and other mammals. It is a 60-amino acid polypeptide produced in the arcuate nucleus of the hypothalamus and the posterior pituitary gland. It is involved in the regulation of appetite and may also have other roles such as in inflammation, sex behavior, and stress. Findings additionally suggest that GALP could play a function in energy metabolism due to its ability to maintain continual activation of the sympathetic nervous system (SNS) via thermogenesis, which refers to the production of heat within living organisms. In addition, the administration of GALP directly into the brain leads to a reduction in the secretion of thyroid-stimulating hormone (TSH), which indicates the involvement of GALP in the neuroendocrine regulation of the hypothalamic-pituitary-thyroid (HPT) axis, and further adding to the evidence of the role of GALP in energy homeostasis.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.

Is TB-500 identical to thymosin beta-4?

No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.

How does TB-500 appear in the literature?

It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.

How should the dry powder be stored?

Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.

Network